MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) News
Latest headlines that mention MLTX, newest first · each headline opens the original publisher
- Last price
- $12.71
- Day change
- +10.23%
- Next earnings
- —
MLTX headlines
latest coverageNot much coverage yet. MLTX has appeared in only a few headlines lately; new stories show up here as publishers cover it.
This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.
The biotech is floating a relatively sizable secondary share issue.
This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a year of sharp share price declines.
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug Administration in April. The post MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket appeared first on Investor's Business Daily .
MLTX news alerts
Get an alert by email or push when a new headline mentions MLTX.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.